novo nordisk glp-1 medications GoodRx, team to make meds affordable Novo Nordisk justifies reasoning behind

doi:10.1161/01.CIR.0000158487.80483.09 Shen X, Zheng S, Metreveli NS, Epstein PN

A clinical trial of once-weekly TZT in T2DM patients illustrated that at 26 weeks of treatment, TZT led to the significant reduction of intercellular adhesion molecule 1 (ICAM-1), growth differentiation factor 15 (GDF-15), chitosan-3 like protein 1 (YKL-40), leptin and CRP compared to the baseline values

ClinicalTrials.gov Coskun T, Urva S, Roell WC, et al

Liraglutide may reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults at lower doses and can improve cardiovascular health metrics and insulin resistance

A patient's existing Part D plan doesn't need to opt in